The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

Expert Opinion on Investigational Drugs

Volumn 8, Issue 5, 1999, Pages 555-566

  Manoharan, G ^a   Maynard, S J ^a   Adgey, A A J ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Acute coronary syndromes; Glycoprotein IIb IIIa inhibitors

Indexed keywords

3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; HEPARIN; LAMIFIBAN; LEFRADAFIBAN; LOTRIFIBAN; ORBOFIBAN; ROXIFIBAN; SIBRAFIBAN; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

BLEEDING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; REVASCULARIZATION; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0032961736     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.8.5.555     Document Type: Review

References (61)